Print this page    •   Back to Web version of article

Intermittent HIV Therapy

By Marshall J. Glesby, MD, Ph.D.

Spring 1999

Temporary discontinuation of antiretroviral therapy under the guidance of a health care provider is sometimes necessary due to severe side effects or other quality of life issues. Because viral loads generally rebound rapidly, such discontinuations -- sometimes called "drug holidays" -- are often felt to be a last resort. But could such temporary rebounds in viral load in other settings have beneficial effects?

The impetus to explore the potential utility of intermittent HIV therapy stems from observations made by Dr. Franco Lori and colleagues involving a person now commonly referred to as the "Berlin patient". This 29-year-old man began treatment with ddI (Videx®), hydroxyurea, and Crixivan® within about a month of presumed initial infection with HIV. He suspended therapy on two occasions due to other concurrent infections, and while he had a rebound in viral load after the first treatment interruption, his viral load remained "undetectable" (less than 500 copies/ml) during the second interruption, which lasted 16 days. He stopped treatment completely after 176 days, and his viral load has remained undetectable for over 18 months.

HIV, however, has been found in his lymph nodes and at a low frequency in his circulating T-cells. This patient has had evidence of vigorous immune responses to HIV. Taken together, it is not clear whether the control of HIV replication in this patient is due to one or more of the following factors: his very early treatment after initial infection, the specific antiretroviral regimen used, and/or intermittent therapy. Perhaps intermittent exposure to HIV antigens during dose interruptions could act like a vaccine and stimulate the body's immune response to the virus, enabling the immune system to control viral replication.

At the Chicago conference, Dr. Lori's group reported preliminary findings which hinted that intermittent therapy may be worthy of further exploration. The researchers treated three patients with stable baseline viral loads ranging from about 23,000 to over 700,000 copies/ml with HAART regimens containing hydroxyurea.

Treatment was given for three weeks, followed by a one-week interruption, and then for two cycles of three months of treatment followed by interruption until viral load rebounded to over 5,000 at which time treatment was reintroduced. Viral load fell back to less than 400 each time treatment was re-started. Interestingly, the time to rebound of viral load to over 5,000 increased with each dose interruption. Rebound time lasted an average of seven days during the first interruption and increased to 14 days and 37 days for the second and third. Parallel studies in rhesus monkeys acutely infected with the related simian immunodeficiency virus (SIV) yielded similar results.

These very preliminary results in only a few patients must be interpreted with caution. In no way do they prove that intermittent therapy or drug holidays are beneficial. Randomized, controlled clinical trials to compare continuous with intermittent therapy are needed and are being planned.


Marshall Glesby is director of Chelsea's Cornell Clinical Trials Unit, and asst. professor of medicine at Cornell University Medical College.


Back to the CRIA Update Spring 99 Contents Page.




This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art14352.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.